What is the price of prevention? New evidence from a field experiment

Journal of Health Economics

Volumn 32, Issue 1, 2013, Pages 207-218

  Okeke, Edward N ^a   Adepiti, Clement A ^b   Ajenifuja, Kayode O ^b  

^a RAND CORPORATION   (United States)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

Demand; Prevention; Prices; Randomized experiment; Subsidies; Testing

Indexed keywords

CANCER; DEVELOPING WORLD; DISEASE TREATMENT; EXPERIMENTAL DESIGN; HEALTH CARE; SUBSIDY SYSTEM;

ADULT; ARTICLE; CANCER SCREENING; CANCER THERAPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; FIELD EXPERIMENT; HEALTH CARE COST; HEALTH PROGRAM; HEALTH SERVICE; HOUSEHOLD; HUMAN; INCOME; NIGERIA; RANDOMIZATION; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; EARLY DETECTION OF CANCER; FEES AND CHARGES; FEMALE; FINANCING, GOVERNMENT; HEALTH SERVICES ACCESSIBILITY; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; NIGERIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

NIGERIA;

EID: 84870289026     PISSN: 01676296     EISSN: 18791646     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2012.10.001     Document Type: Article

References (42)

1. Ashraf N., Berry J.N., Shapiro J.M. Can higher prices stimulate product use? Evidence from a field experiment in Zambia. American Economic Review 2010, 100(5):2383-2413.
2. Bishop A., Wells E., Sherris J., Tsu V., Crook B. Cervical cancer: evolving prevention strategies for developing countries. Reproductive Health Matters 1995, 6:60L 71.
3. Bitler M., Gelbach J., Hoynes H. What mean impacts miss: distributional effects of welfare reform experiments?. American Economic Review 2005, 96(4):988-1012.
4. Brinton L. Epidemiology of cervical cancer-overview. The Epidemiology of Human Papillomavirus and Cervical Cancer 1992, IARC Scientific Publication 119. Environmental Epidemiology Branch National Cancer Institute, Bethesda, MD 20892, pp. 3-23.
5. Caplin A., Leahy J. Psychological expected utility and anticipatory feelings?. Quarterly Journal of Economics 2001, 116(1):55-80.
6. Cohen J., Dupas P. Free distribution or cost-sharing? Evidence from a randomized malaria prevention experiment. Quarterly Journal of Economics 2010, 125(1):1-45.
7. Cohen, J., Dupas, P., Schaner, S., 2011. Price Subsidies, Diagnostic Tests, and Targeting of Malaria Treatment: Evidence from a Randomized Controlled Trial. Mimeo.
8. Cropper M.L. Health, investment in health and occupational choice. Journal of Political Economy 1977, 85:1273-1294.
9. Cullins V.E., Wright T.C., Beattie K.J., Pollack A.E. Cervical cancer prevention using visual screening methods?. Reproductive Health Matters 1999, 7(14):134-143.
10. Devoto F., Duflo E., Dupas P., Pons V., Pariente W. Happiness on Tap: Piped Water Adoption in Urban Morocco 2011, SSRN eLibrary.
11. Eddy D. Screening for Cancer: Theory, Analysis and Design 1980, Prentice-Hall, Englewood Cliffs, NJ.
12. Gakidou E., Nordhagen S., Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Medicine 2008, 5(6):e132.
13. Glynn J.R., Kayuni N., Banda E., Parrott F., Floyd S., Francis-Chizororo M., Nkhata M., Tanton C., Hemmings J., Molesworth A., Crampin A.C., French N. Assessing the validity of sexual behaviour reports in a whole population survey in rural Malawi. PLoS ONE 2011, 6(7):e22840.
14. Grossman M. On the concept of health capital and the demand for health. Journal of Political Economy 1972, 80:223-225.
15. Heckman J., Smith J., Clements N. Making the most out of programme evaluations and social experiments: accounting for heterogeneity in programme impacts?. Review of Economic Studies 1997, 64(4):487-535.
16. Hewett P.C., Mensch B.S., Erulkar A.S. Consistency in the reporting of sexual behaviour by adolescent girls in Kenya: a comparison of interviewing methods. Sexually Transmitted Infections 2004, 80(Suppl. 2):ii43-ii48.
17. Hurd M., McGarry K. Evaluation of the subjective probabilities of survival in the Health and Retirement Study. Journal of Human Resources 1995, 268-292.
18. IARC IARC Handbook of Cancer Prevention 2004, vol. 10. IARC Press, Lyon.
19. James C., Hanson K., McPake B., Balabanova D., Gwatkin D., Hopwood I., Kirunga C., Knippenberg R., Meessen B., Morris S., Preker A., Souteyrand Y., Tibouti A., Villeneuve P., Xu K. To retain or remove user fees? Reflections on the current debate in low- and middle-income countries. Applied Health Economics and Health Policy 2006, 5(3):137-153.
20. Kenkel D.S. The demand for preventive care. Applied Economics 1994, 26:313-325.
21. Kenkel D.S. Prevention: vol. 1. Handbook of Health Economics 2000, Elsevier, pp. 1675-1720 (Chapter 31).
22. Koszegi B. Health anxiety and patient behavior. Journal of Health Economics 2003, 22(6):1073-1084.
23. Kremer M., Miguel E. The illusion of sustainability?. Quarterly Journal of Economics 2007, 112(3):1007-1065.
24. Lartey M., Joubert G., Cronje H.S. Knowledge, attitudes and practices of rural women in South Africa regarding the Pap smear. International Journal of Gynecology and Obstetrics 2003, 83:315-316.
25. Lazcano-Ponce E., Moss S., Alonso de Ruiz P., Castro J., Hernandez-Avila M. Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico. Archives of Medical Research 1999, 30:240-250.
26. Lerman C., Marshall J., Audrain J., Gomez-Caminero A. Genetic testing for colon cancer susceptibility: anticipated reactions of patients and challenges to providers?. International Journal of Cancer 1996, 69(1):58-61.
27. Miguel E., Kremer M. Worms: identifying impacts on education and health in the presence of treatment externalities?. Econometrica 2004, 72(1):159-217.
28. Mocan H., Tekin E., Zax J.S. The demand for medical care in urban China. World Development 2004, 32(2):289-304.
29. Oster, E., Dorsey, R., Shoulson, I. Optimal expectations and limited medical testing: evidence from Huntington disease. American Economic Review, forthcoming.
30. Parkin, D.M., Whelan, S.L., Ferlay, J., Thomas, D.B., Teppo, L., 2002. Cancer incidence in five continents. Technical report, IARC Scientific Publications, No. 155. International Agency for Research on Cancer.
31. Picone G., Sloan F., Taylor D. Effects of risk and time preference and expected longevity on demand for medical tests?. The Journal of Risk and Uncertainty 2004, 28(1):39-53.
32. Sankaranarayanan R. Overview of cervical cancer in the developing world. International Journal of Gynecology and Obstetrics 2006, 95(Suppl. 1):S205-S210.
33. Sankaranarayanan R., Budukh A., Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bulletin of the World Health Organization 2001, 79:954-962.
34. Sasieni P.D., Adams J. Standardized lifetime risk?. American Journal of Epidemiology 1999, 149(9):869-875.
35. Schiffman M.H., Brinton L. The epidemiology of cervical carcinogenesis. Cancer 1995, 76:1888L 1901.
36. Tarozzi, A., Mahajan, A., Blackburn, B., Kopf, D., Krishnan, L., Yoong, J., 2011. Micro-Loans, Insecticide-Treated Bednets and Malaria: Evidence from a Randomized Controlled Trial in Orissa (India). Economic Research Initiatives at Duke (ERID) Working Paper No. 104.
37. Thornton R. The demand for, and impact of, learning HIV status. American Economic Review 2008, 98(5):1829-1863.
38. Walboomers J.M., Jacobs, Manos M.M., Bosch F.X., Kummer J.A., Shah K.V. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 1999, 189:1-3.
39. Walraven G. Prevention of cervical cancer in Africa: a daunting task?. African Journal of Reproductive Health 2003, 7(2):7-12.
40. Warwick Z. The influence of antiretroviral therapy on the uptake of HIV testing in Tutume, Botswana. International Journal of STD and AIDS 2006, 17(7):479-481.
41. Wilson, N., 2010. Antiretroviral Therapy and Demand for HIV Testing: Evidence from Zambia. Mimeo, WIlliams College.
42. World Health Organization, 2002. Cervical Cancer Screening in Developing Countries: Report of a WHO Consultation. World Health Organization, Geneva.